Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | CPT2 | P23786 | 1/20 | 0.49 |
| ▸ | CPT1A | P50416 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789072 | 1.00 | ACE (0.55) | ACEALDH1A1SMN1; SMN2ACE2LTA4H | |
| Trifluoroacetic Acid SCHEMBL6789947 | 0.93 | ACE (0.52) | ACEACE2LTA4H | |
| SCHEMBL7300099 | 0.91 | ACE (0.47) | ACEALDH1A1SMN1; SMN2ACE2LTA4H | |
| SCHEMBL6786452 | 0.88 | ACE (0.52) | ACEALDH1A1SMN1; SMN2ACE2LTA4H | |
| SCHEMBL6786455 | 0.88 | ACE (0.52) | ACEALDH1A1SMN1; SMN2ACE2LTA4H | |
| SCHEMBL6789950 | 0.86 | ACE (0.44) | ACEALDH1A1SMN1; SMN2ACE2CPT2 | |
| SCHEMBL6787852 | 0.83 | KLK5 (0.52) | ACECPT2CPT1A | |
| SCHEMBL6787840 | 0.83 | KLK5 (0.52) | ACECPT2CPT1A | |
| SCHEMBL474618 | 0.82 | ACE (0.60) | ACEALDH1A1SMN1; SMN2ACE2LTA4H | |
| SCHEMBL474742 | 0.82 | ACE (0.60) | ACEALDH1A1SMN1; SMN2ACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | claimed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | claimed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | claimed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | ACE 1460/4885ALDH1A1 175/4885SMN1; SMN2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.